1. Articles from Wang X , et al.

    1-2 of 2
    1. miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10.

      miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10.

      Biomed Pharmacother. 2018 Jul;103:1312-1318

      Authors: Wang X, Li J, Xu X, Zheng J, Li Q

      Abstract Although the treatment strategies for neuroblastoma (NB) develop rapidly, a considerable number of patients could not benefit from chemotherapy. Here, we revealed a miR-129-MYO10 axis that regulated neuroblastoma growth and chemosensitivity.

      Read Full Article
    1-2 of 2
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (1 articles) NSE
    2. (1 articles) LDH
    3. (1 articles) Treatment
    4. (1 articles) Chemotherapy
  3. Popular Articles

  4. Picture Gallery

    Exercise linked to reduced mortality in survivors of childhood cancer Life-extending immunotherapy approved on NHS for children with neuroblastoma Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma Fluorescent zebrafish genes provide clues about neuroblastoma An Intermediate Expanded Use Trial of DFMO Fluorescent fish genes light path to neuroblastoma Nanoparticles give immune cells a boost MabVax Therapeutics sublicenses therapeutics for patented neuroblastoma vaccine St. Jude Children’s Research Hospital launches public repository of pediatric cancer genomics data Polymorphisms in MYCN gene and neuroblastoma risk in Chinese children: a 3-center case ... A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy